The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

Solifenacin succinate 1mg/mL; oral susp; orange-flavor. Take once daily, followed by liquid (eg, water or milk). Avoid taking at the same time with food or other drinks. Missed dose: take as soon ...

Vesicare is the first overactive bladder treatment at an approved dose to show a statistically significant increase in warning time before urination Christchurch, New Zealand – December 1 ...

On Nov. 22, the FDA approved solifenacin succinate (Vesicare, made by Yamanouchi Pharmaceutical Co., Ltd., and GlaxoSmithKline) for the treatment of overactive bladder (OAB) with symptoms of ...

Clinical data and expert opinion show that Astellas/GlaxoSmithKline's Vesicare has advantages in this attribute over the market sales leader, Pfizer's Detrol LA/ Detrusitol XL. The new report ...

CHICAGO Patients with overactive bladder who received the drug Vesicare reported lower incidence of dry mouth than those who received an immediate-release formulation of the generic drug ...

VESIcare LS is an oral suspension dosage form that was specifically developed to facilitate dosing and administration in the pediatric population. VESIcare (solifenacin succinate) tablets were ...

The US Food and Drug Administration (FDA) has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate (Vesicare, Astellas Pharma) for the treatment of overactive ...

Hi Doc Thanks for the reply to my earlier question about taking Vesicare & Trepiline for my bladder problems. I would just like to please know could I not change the dosage of Trepiline to, say, 25mg ...

VESIcare (solifenacin succinate) tablets were approved in 2004 to treat overactive bladder in patients 18 years and older. VESIcare LS is the first FDA-approved treatment for NDO in patients as ...